News of Note—Sun Pharma slapped with Form 483; Catalent invests $14M; FDA draft guidance

iPhone
(Pixabay)

> Sun Pharmaceutical has been issued a Form 483 with 11 observations for its plant in Dadra, India. Story

> Somerset, New Jersey-based Catalent is investing $14 million to expand softgel capabilities at its facility in Eberbach, Germany, in response to demand for animal-free consumer health products. Release

> The FDA has issued new draft guidance for how companies should handle voluntary recalls. Release

> East Rutherford, New Jersey-based CDMO Cambrex has opened a new 120-square-meter quality control laboratory at its site in Milan, Italy. Release

 

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

CanSino reports positive data for COVID-19 vaccine. Takeda's Alunbrig wins first-line lung cancer nod. GSK inks $231 million deal with Samsung.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.